Rachael Lawrance

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

Geoffrey R. Oxnard, Kenneth S. Thress, Ryan S. Alden et al. · Journal of Clinical Oncology · 2016 · 843 citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Martin Reck, Michael Schenker, Ki Hyeong Lee et al. · European Journal of Cancer · 2019 · 217 citations · Full text

Medicine, Oncology, Pharmacology +17

Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in<i>P2RY12, P2RY1,</i>and<i>ITGB3</i>

Robert F. Storey, Sophia Thornton, Rachael Lawrance et al. · Platelets · 2009 · 66 citations

Medicine, Pharmacology, Pharmacotherapy +17

Classification of rheumatoid arthritis status with candidate gene and genome-wide single-nucleotide polymorphisms using random forests

Yan V. Sun, Zhaohui Cai, Kaushal Desai et al. · BMC Proceedings · 2007 · 34 citations · Full text

Life Sciences, Biostatistics, Genetics +17

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743

Arnaud Scherpereel, Scott Antonia, Francesco Grossi et al. · Lung Cancer · 2022 · 34 citations · Full text

Medicine, Oncology, Pharmacotherapy +17